<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title>PLoS ONE</journal-title><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">09-PONE-RA-09380</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0005843</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Radiology and Medical Imaging</subject><subject>Oncology/Breast Cancer</subject><subject>Radiology and Medical Imaging/Computer Tomography</subject></subj-group></article-categories><title-group><article-title>Tumor Vascular Permeability to a Nanoprobe Correlates to Tumor-Specific Expression Levels of Angiogenic Markers</article-title><alt-title alt-title-type="running-head">Vascular Permeability and VEGF</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Karathanasis</surname><given-names>Efstathios</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="author-notes" rid="fn1"><sup>&#x000a4;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chan</surname><given-names>Leslie</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Karumbaiah</surname><given-names>Lohitash</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>McNeeley</surname><given-names>Kathleen</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>D'Orsi</surname><given-names>Carl J.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Annapragada</surname><given-names>Ananth V.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sechopoulos</surname><given-names>Ioannis</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bellamkonda</surname><given-names>Ravi V.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology/Emory University, Atlanta, Georgia, United States of America</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Department of Radiology and Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, United States of America</addr-line></aff><aff id="aff3"><label>3</label><addr-line>School of Health Information Sciences, University of Texas at Houston, Houston, Texas, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Aziz</surname><given-names>Syed A.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Health Canada, Canada</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>ravi@gatech.edu</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: EK RVB. Performed the experiments: EK LC LK KM IS. Analyzed the data: EK LC LK. Contributed reagents/materials/analysis tools: EK LK CJD. Wrote the paper: EK CJD AVA IS RVB.</p></fn><fn id="fn1" fn-type="current-aff"><label>&#x000a4;</label><p>Current address: Department of Biomedical Engineering and Case Center for Imaging Research, Case Western Reserve University, Cleveland, Ohio, United States of America</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>9</day><month>6</month><year>2009</year></pub-date><volume>4</volume><issue>6</issue><elocation-id>e5843</elocation-id><history><date date-type="received"><day>24</day><month>3</month><year>2009</year></date><date date-type="accepted"><day>11</day><month>5</month><year>2009</year></date></history><copyright-statement>Karathanasis et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2009</copyright-year><abstract><sec><title>Background</title><p>Vascular endothelial growth factor (VEGF) receptor-2 is the major mediator of the mitogenic, angiogenic, and vascular hyperpermeability effects of VEGF on breast tumors. Overexpression of VEGF and VEGF receptor-2 is associated with the degree of pathomorphosis of the tumor tissue and unfavorable prognosis. In this study, we demonstrate that non-invasive quantification of the degree of tumor vascular permeability to a nanoprobe correlates with the VEGF and its receptor levels and tumor growth.</p></sec><sec><title>Methodology/Principal Findings</title><p>We designed an imaging nanoprobe and a methodology to detect the intratumoral deposition of a 100 nm-scale nanoprobe using mammography allowing measurement of the tumor vascular permeability in a rat MAT B III breast tumor model. The tumor vascular permeability varied widely among the animals. Notably, the VEGF and VEGF receptor-2 gene expression of the tumors as measured by qRT-PCR displayed a strong correlation to the imaging-based measurements of vascular permeability to the 100 nm-scale nanoprobe. This is in good agreement with the fact that tumors with high angiogenic activity are expected to have more permeable blood vessels resulting in high intratumoral deposition of a nanoscale agent. In addition, we show that higher intratumoral deposition of the nanoprobe as imaged with mammography correlated to a faster tumor growth rate. This data suggest that vascular permeability scales to the tumor growth and that tumor vascular permeability can be a measure of underlying VEGF and VEGF receptor-2 expression in individual tumors.</p></sec><sec><title>Conclusions/Significance</title><p>This is the first demonstration, to our knowledge, that quantitative imaging of tumor vascular permeability to a nanoprobe represents a form of a surrogate, functional biomarker of underlying molecular markers of angiogenesis.</p></sec></abstract><counts><page-count count="9"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Angiogenesis is a critical event enabling tumor growth <xref ref-type="bibr" rid="pone.0005843-Ferrara1">&#x0005b;1&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005843-Folkman1">&#x0005b;3&#x0005d;</xref>. Vascular endothelial growth factor (VEGF) and receptor (VEGFR) signaling pathway plays a pivotal and rate-limiting role in promoting tumor-induced angiogenesis <xref ref-type="bibr" rid="pone.0005843-Ferrara1">&#x0005b;1&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005843-Ferrara2">&#x0005b;2&#x0005d;</xref>. Angiogenesis correlates not only with the onset of tumor development but also with growth, metastasis and invasion of tumors <xref ref-type="bibr" rid="pone.0005843-Folkman2">&#x0005b;4&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005843-StetlerStevenson1">&#x0005b;5&#x0005d;</xref>. It is now established that VEGFR-2 is the major mediator of the mitogenic, angiogenic, and vascular hyperpermeability effects of VEGF <xref ref-type="bibr" rid="pone.0005843-Ferrara3">&#x0005b;6&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005843-CebeSuarez1">&#x0005b;9&#x0005d;</xref>.</p><p>Like most tumors, breast tumors express many angiogenic factors, such as VEGF and VEGFR, fibroblast growth factor (FGF)-1, FGF-2, angiopoietin-1 and 2, placenta growth factor, hypoxia-inducible factor (HIF)-1&#x003b1;, endothelial cell adhesion molecules (VE-cadherin, PECAM-1), epidermal growth factor, TGF-&#x003b1; and TGF-&#x003b2; <xref ref-type="bibr" rid="pone.0005843-Fox1">&#x0005b;10&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005843-Nikitenko1">&#x0005b;13&#x0005d;</xref>. Notably, various clinical studies demonstrate that higher levels of VEGF overexpression in the tumor correlate with unfavorable prognosis <xref ref-type="bibr" rid="pone.0005843-Gasparini1">&#x0005b;14&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005843-Linderholm1">&#x0005b;16&#x0005d;</xref>. Indeed, there is a strong positive correlation between VEGF and VEGFR-2 expression and primary breast cancers and this correlation scales to the degree of pathomorphosis of the primary tissue <xref ref-type="bibr" rid="pone.0005843-Kim1">&#x0005b;17&#x0005d;</xref>. Therefore markers of angiogenesis may describe the degree of pathomorphosis of breast cancers and quantitative assessment of these markers may have significant clinical implications. However, it is challenging to non-invasively determine the expression profiles of the angiogenesis-related factors <xref ref-type="bibr" rid="pone.0005843-Ferrara1">&#x0005b;1&#x0005d;</xref>. However, as angiogenesis transiently yields immature vessels, they result in &#x02018;leaky&#x02019; microvessels. In the recent past, dynamic contrast-enhanced imaging (DCE-MRI) has been employed to measure tumor vascular permeability to sub 2 nm scale or 5&#x02013;10 nm scale contrast agents <xref ref-type="bibr" rid="pone.0005843-Raatschen1">&#x0005b;18&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005843-Miller1">&#x0005b;20&#x0005d;</xref>. Tumor signal enhancement is influenced by the degree of vascularization, vessel permeability, cellularity and interstitial pressure <xref ref-type="bibr" rid="pone.0005843-Nunes1">&#x0005b;21&#x0005d;</xref>. However, while these approaches are promising, small contrast agents are relatively promiscuous in their leakiness from vessels and diffuse away quickly requiring the use of mathematical models to correlate the dynamic changes in signal enhancement to the physiologic parameters associated with vascular function <xref ref-type="bibr" rid="pone.0005843-Brix1">&#x0005b;22&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005843-Tofts2">&#x0005b;25&#x0005d;</xref>. In addition, molecular imaging of angiogenesis biomarkers using positron emission tomography is beginning to be feasible <xref ref-type="bibr" rid="pone.0005843-Chen1">&#x0005b;26&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005843-Chen2">&#x0005b;27&#x0005d;</xref>.</p><p>Here, we investigate a 100 nm nanoprobe, which enables quantification of tumor vessel permeability in a manner that is reliable, and not requiring complex analysis of diffusion dynamics. Due to its size, the 100 nm nanoprobe preferentially accumulates in solid tumors by passive convective transport through leaky endothelium, a phenomenon called the enhanced permeation and retention (EPR) effect <xref ref-type="bibr" rid="pone.0005843-Maeda1">&#x0005b;28&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005843-Maeda2">&#x0005b;29&#x0005d;</xref>. In addition, we investigate whether tumor vascular permeability represents a functional biomarker that scales to the levels of VEGF and VEGFR-2 overexpression in tumors. Traditionally biomarkers are cell surface or intracellular molecular markers &#x02013; here we suggest that the degree of leakiness of tumor blood vessels &#x02018;integrates&#x02019; underlying tumor microenvironmental factors related to angiogenesis, and represents the underlying tumor pathomorphological status. The nanoprobe encapsulates a clinically used iodinated contrast agent for x-ray imaging that enables a quantitative assessment of tumor vessel leakiness using clinically relevant digital mammography <xref ref-type="bibr" rid="pone.0005843-Karathanasis1">&#x0005b;30&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005843-Karathanasis2">&#x0005b;31&#x0005d;</xref>. Taking under consideration that mammography is the only method of low cost mass screening of the general population for non-palpable breast cancer <xref ref-type="bibr" rid="pone.0005843-Pisano1">&#x0005b;32&#x0005d;</xref>, is widely available and quick and has a very high spatial resolution, such imaging strategy can be very practical. Using a breast cancer tumor model where the tumor EPR of individual rats varies widely <xref ref-type="bibr" rid="pone.0005843-Karathanasis1">&#x0005b;30&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005843-Karathanasis2">&#x0005b;31&#x0005d;</xref>, this study evaluates whether this variation of tumor EPR to nanoscale probes, correlates to underlying variation in expression of tumor angiogenic markers.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and Methods</title><sec id="s2a"><title>Ethics Statement</title><p>All animals were handled in strict accordance with good animal practice as defined by the relevant national and/or local animal welfare bodies, and all animal work was approved by the Institutional Animal Care and Use Committee (IACUC) of Georgia Institute of Technology.</p></sec><sec id="s2b"><title>Fabrication of the nanoprobe</title><p>The nanoprobe was prepared following previously published methods <xref ref-type="bibr" rid="pone.0005843-Karathanasis2">&#x0005b;31&#x0005d;</xref>. A highly concentrated iodine solution (650 mg I/mL) was prepared by dissolving iodixanol powder (lyophilized from Visipaque 320; GE Healthcare, Milwaukee, WI) in ultrapure water under stirring and heating at 70&#x000b0;C. A lipid composition of DPPC, DSPE-PEG<sub>2000</sub> (Genzyme Pharmaceuticals, Cambridge, MA), and cholesterol (Sigma, St. Louis, MO) in the molar ratio of 55&#x02236;5&#x02236;40 was used. The lipids were dissolved in ethanol and hydrated with the iodine solution at 70&#x000b0;C followed by sequential extrusion in a Lipex Biomembranes Extruder (Northern Lipids, Vancouver, Canada) to size the liposomes to &#x0223c;100 nm. Free, un-encapsulated iodixanol was replaced by a saline solution (300 mM NaCl) with the same osmolarity (596 mOsm/kg water) as the internal iodinated phase of the liposome using a 2-day dialysis with a 100k MWCO dialysis tubing. Following concentration via diafiltration using MicroKros modules (Spectrum Laboratories, Rancho Dominguez, CA) with a 50 nm cutoff pore size, the size of the liposomes was determined by dynamic light scattering (90 Plus Particle Size Analyzer, Brookhaven Instruments, Holtsville, NY). Prior to administration, the final iodine levels were quantified through spectrophotometry (at 245 nm). The liposomal probe contained 75 mg/ml lipids and 165 mg/mL iodine and 100&#x00025; of the iodine was encapsulated within the liposomes. The average diameter of the probe was 102 nm (standard deviation&#x0200a;&#x0003d;&#x0200a;11).</p></sec><sec id="s2c"><title>Mammary adenocarcinoma cell culture</title><p>The 13762 MAT B III cells (American Type Culture Collection), a rat mammary adenocarcinoma cell line, were maintained in McCoy's 5A medium supplemented with 10&#x00025; fetal bovine serum and 1&#x00025; penicillin-streptomycin under conditions of 5&#x00025; CO<sub>2</sub> and 95&#x00025; humidity at 37&#x000b0;C.</p></sec><sec id="s2d"><title>Animal model</title><p>For the tumor model, the 13762 MAT B III cell line was used. Before inoculation, the cells were grown in 90&#x00025; McCoy's 5A medium and 10&#x00025; fetal bovine serum. A 0.2 mL aliquot containing 10<sup>6</sup> cancer cells was subcutaneously injected into the right flank of female Fisher rats with ages of 8&#x02013;9 weeks (Harlan, Indianapolis, IN). Caliper measurements were used to estimate tumor size and the tumor volume was calculated as: V<sub>tumor</sub>&#x0200a;&#x0003d;&#x0200a;(d<sub>1</sub><sup>2</sup>&#x000d7;d<sub>2</sub>)/2, where d<sub>1</sub> and d<sub>2</sub> are the minimum and maximum diameters, respectively.</p></sec><sec id="s2e"><title>X-ray imaging</title><p>At day 7 after tumor inoculation (tumor volume &#x0223c;500 mm<sup>3</sup>), the animals were imaged using a clinical digital mammography system (Senographe 2000D, GE Healthcare, Milwaukee, WI). To maximize the number of photons with energies above the K-edge of iodine (approx. 33.2 keV) <xref ref-type="bibr" rid="pone.0005843-Hubbell1">&#x0005b;33&#x0005d;</xref>, the imaging studies were performed with a 49 kVp, 63 mAs x-ray spectrum, using a rhodium target and a 25 &#x000b5;m thick rhodium filter with an added 0.254 mm thick copper filter.</p><p>After the initial imaging session at day 7 after tumor inoculation (t&#x0200a;&#x0003d;&#x0200a;0), a group of animals (group A, n&#x0200a;&#x0003d;&#x0200a;6) was imaged at defined time points (t&#x0200a;&#x0003d;&#x0200a;24, and 72 h) after intravenous (IV) injection of the probe at a dose of 455 mg/kg body weight (b.w.) iodine. Immediately after the last imaging session, the animals were euthanized, tumors were excised, and total RNA was extracted for quantitative real-time reverse transcriptase-polymerase chain reaction (qRT-PCR). Care was taken to obtain the entire tumor without any surrounding tissue.</p><p>To evaluate whether the degree of EPR scales to the tumor growth rate, a different group of animals (group B, n&#x0200a;&#x0003d;&#x0200a;11) was imaged before (t&#x0200a;&#x0003d;&#x0200a;0) and at defined time points (t&#x0200a;&#x0003d;&#x0200a;24, 48 and 120 h) after IV injection of the probe at a dose of 455 mg/kg b.w. iodine at day 7 after tumor inoculation. The tumor growth of each animal was monitored at 24 h intervals using caliper measurements. Tumor growth was allowed to progress until the animal showed signs of morbidity, at which point, the animals were euthanized using a CO<sub>2</sub> chamber.</p></sec><sec id="s2f"><title>Quantitative RT-PCR</title><p>qRT-PCR was used to quantify mRNA expression profiles of genes that are closely associated with angiogenesis. Immediately after completion of imaging, the animals of group A were euthanized and tumors were excised. Total RNA was extracted from the entire tumor and muscle (control) of each animal (n&#x0200a;&#x0003d;&#x0200a;6) by using RNeasy Maxi RNA extraction kit (Qiagen, Chatsworth, CA) and the protocols therein. Purified RNA was quantified using the Quant-IT Ribogreen reagent (Invitrogen Life Technologies, Carlsbad, CA). Total RNA (2 &#x000b5;g) was converted into cDNA by using Thermoscript RT-PCR system (Invitrogen Life Technologies, Carlsbad, CA). Primers targeting VEGF-A (NM_031836.1) Forward&#x02013; <named-content content-type="gene">CGTCTACCAGCGCAGCTATTG</named-content> and Reverse- <named-content content-type="gene">CACACAGGACGGCTTGAAGAT</named-content>; KDR (VEGFR-2) (NM_013062.1) Forward- <named-content content-type="gene">TTGGCAAATACAACCCTTCAGAT</named-content> and Reverse- <named-content content-type="gene"> CACTCAGTCACCAACACCCTTTC</named-content>; and endogenous control hypoxanthine phosphoribosyltransferase-1 (HPRT1) (NM_012583.2) Forward &#x02013; <named-content content-type="gene">TGTTTGTGTCATCAGCGAAAGTG</named-content> and Reverse - <named-content content-type="gene">CTGCTAGTTCTTTACTGGCCACATC</named-content> were designed using Primer Express 3.0 software (Applied Biosystems, Foster city, CA), to yield an amplicon of &#x0223c;100 base-pair length. PCR amplification efficiencies were assessed for each primer-set using cDNA equivalents of 1, 2, 5, 10, 20, 50 and 100 ng of total RNA. qRT-PCR was conducted on an ABI Step-One-Plus real-time PCR system (Applied Biosystems, Foster City, CA) in 20 &#x000b5;l reactions. Each reaction consisted of a cDNA equivalent of 20 ng of total RNA, 10 &#x000b5;l Power&#x000ae; SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) and forward and reverse primers at 0.9 &#x000b5;M concentration. Each sample was assayed in triplicate for both target and endogenous control, and relative quantitative gene expression was assessed using the &#x00394;&#x00394;CT method. The levels of target gene expression were calculated following normalization of endogenous control for each sample, and presented as relative units. The relative gene expression of each tumor was computed by normalizing its value to the tumor with the highest value (a value of 1 corresponds to the tumor with the highest gene expression).</p></sec><sec id="s2g"><title>Histological analysis</title><p>For a qualitative histological validation of the imaging and qRT-PCR studies, a separate group of animals (group C, n&#x0200a;&#x0003d;&#x0200a;2) was injected at day 7 with the probe at a dose of 455 mg/kg b.w. iodine tagged with rhodamine. At 48-h post-injection, the animals were perfused transcardially with phosphate buffered saline (PBS) followed by 4&#x00025; paraformaldehyde in PBS. The tumors were explanted and post-fixed overnight in 4&#x00025; paraformaldehyde in PBS. The fixed tumors were soaked in 30&#x00025; sucrose (w/v) in PBS at 4&#x000b0;C for cryosectioning. Serial sections of 16 &#x000b5;m thickness were collected using a cryostat (Leica CM 300, Leica, Bannockburn, IL). The tissue slices were immunohistochemically stained for VEGFR-2 using a mouse monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA). The tissues were also stained with the nuclear stain DAPI. The staining procedures followed established methods <xref ref-type="bibr" rid="pone.0005843-Karathanasis3">&#x0005b;34&#x0005d;</xref>. The tumor sections were imaged at 4&#x000d7; on the Nikon Eclipse 80i upright microscope using a Microfire CCD camera (Optronics, Golate, CA) that interfaced with the Neurolucida software (MicroBrightField Bioscience, Williston, VT) to obtain a montage of each section. The histological analysis was performed to verify the presence of extravascular intratumoral accumulation of the probe and its location with respect to the tumor vasculature and VEGFR-2 expression.</p></sec><sec id="s2h"><title>Image analysis</title><p>The sequential image acquisitions at different time points provided the dynamics of the nanoprobe's accumulation in the tumor over time. The images were analyzed using ImageJ software (NIH, Bethesda, MD) following previously described methods <xref ref-type="bibr" rid="pone.0005843-Karathanasis1">&#x0005b;30&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005843-Karathanasis2">&#x0005b;31&#x0005d;</xref>.</p></sec><sec id="s2i"><title>Data and statistical analysis</title><p>To determine the significance of the relative gene expression levels of the tumors, one-way ANOVA with post-hoc Bonferroni test was performed (SPSS 15, Chicago, IL). A p-value less than 0.05 was used to confirm significant differences at the 95&#x00025; confidence level. The Anderson-Darling test was performed to verify that the data followed a normal distribution. The tumor signal enhancement profiles and tumor growth curves were fitted into an exponential function <xref ref-type="bibr" rid="pone.0005843-Brown1">&#x0005b;35&#x0005d;</xref> using nonlinear regression (Levenberg-Marquardt algorithm) to compute the enhancement rate constant (K<sup>enhancement</sup>) and the tumor growth rate constant (K<sup>tumor growth</sup>), respectively. The K<sup>enhancement</sup> and K<sup>tumor growth</sup> constants represent a measure of each animal's tumor vascular permeability to the probe and its tumor growth, respectively. The correlation between the signal enhancement and the tumor growth rate or relative gene expression was determined using Pearson's correlation. A p-value less than 0.05 was used to confirm significant differences at the 95&#x00025; confidence level. The correctness of the model was determined by examining the residuals plots and other statistical tests.</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Tumor imaging</title><p>To eliminate signal from the blood vessels and transparently image the EPR of the probe, contrast-enhanced imaging was performed with IV injection of the probe at a dose of 455 mg/kg b.w. iodine which resulted in a concentration below the threshold for detection of iodine in the blood <xref ref-type="bibr" rid="pone.0005843-Karathanasis2">&#x0005b;31&#x0005d;</xref>. This allowed detection of the intratumoral extravascular deposition of the probe with no interference from vascular signal. <xref ref-type="fig" rid="pone-0005843-g001">Fig. 1</xref> shows the pre-injection (t&#x0200a;&#x0003d;&#x0200a;0) and post-injection images (t&#x0200a;&#x0003d;&#x0200a;24 and 72 h). In the post-injection images, no blood vessels were visible in the normal tissue while the spleen and the tumor were enhanced. Spleen enhancement is consistent with clearance of the liposomal probe via the Reticulo Endothelial System (RES) <xref ref-type="bibr" rid="pone.0005843-Lasic1">&#x0005b;36&#x0005d;</xref>.</p><fig id="pone-0005843-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005843.g001</object-id><label>Figure 1</label><caption><title>Radiographic images of a rat breast tumor model obtained using a clinical digital mammography system.</title><p>The images display the 3-day intratumoral fate of the probe (a) before, (b) 24 and (c) 72 h after administration of the probe at a dose of 455 mg/kg b.w. iodine. In the post-injection images no blood vessels were visible in the normal tissue while spleen and tumor were clearly seen. Yellow and brown dotted circles indicate the location of the tumor and spleen, respectively. In the insets, a magnification (5&#x000d7;) of the tumor at each time point is shown.</p></caption><graphic xlink:href="pone.0005843.g001"/></fig></sec><sec id="s3b"><title>Correlation of angiogenesis biomarkers to EPR imaging</title><p>When tumors were monitored for 3 days post-injection, it was observed that the x-ray absorption in tumors due to extravascular nanoprobe varied widely both spatially and temporally suggesting that each tumor had different tumor vessel leakiness. <xref ref-type="fig" rid="pone-0005843-g002">Fig. 2</xref>.a summarizes the 3-day time course of the tumor enhancement of a group of animals injected with the nanoprobe (group A). Following imaging, the animals were euthanized, tumors were excised, and total RNA was extracted for qRT-PCR. A significant difference in the gene levels can be observed from one animal to the next (<xref ref-type="fig" rid="pone-0005843-g002">Fig. 2.b</xref>). Some tumors displayed 3&#x02013;5 times less VEGF and VEGFR-2 than others. Importantly, the relative gene expression level of each tumor strongly correlated to its tumor enhancement as imaged by mammography (<xref ref-type="fig" rid="pone-0005843-g002">Fig. 2.c and d</xref>).</p><fig id="pone-0005843-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005843.g002</object-id><label>Figure 2</label><caption><title>Comparison of the imaging-based EPR measurements to gene expression of VEGF and VEGFR-2.</title><p>(a) The 3-day pattern of the enhancement upon injection of the probe to a group of rats (n&#x0200a;&#x0003d;&#x0200a;6) indicated a high variability in the tumors leakiness. (b) Relative gene expression of VEGF and VEGFR-2 as measured using qRT-PCR also exhibited a high variability (&#x0002a; indicates p&#x0003c;0.005; data presented as mean&#x000b1;standard deviation). (c&#x02013;d) The relative gene expression level of each tumor was strongly correlated to its tumor enhancement as imaged by mammography (VEGF-A&#x02236; R<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;0.873, p&#x0003c;0.005; VEGFR-2&#x02236; R<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;0.824, p&#x0003c;0.002). Each animal is assigned the same color in all the graphs (e.g. purple indicates animal number 4).</p></caption><graphic xlink:href="pone.0005843.g002"/></fig></sec><sec id="s3c"><title>Histological evaluation of intratumoral distribution of the probe</title><p>In a previous study <xref ref-type="bibr" rid="pone.0005843-Karathanasis2">&#x0005b;31&#x0005d;</xref>, we showed the MAT B III tumor is characterized by a highly vascularized peripheral rim and an internal core with low vascularization. Notably, the extravasated nanoprobes were localized in the well-vascularized periphery of the tumor in a patchy distribution. In the current study, immunofluorescence microscopy was performed to qualitatively determine the microdistribution of VEGFR-2 and nanoprobe deposition. As shown in <xref ref-type="fig" rid="pone-0005843-g003">Fig. 3.a</xref>, VEGFR-2 (shown in green) is predominantly found in the periphery whereas lower levels are seen in the inner core of the tumor. The nanoprobe (shown in red) localized in the periphery of the tumor showing a patchy distribution similar to our previous observations <xref ref-type="bibr" rid="pone.0005843-Karathanasis2">&#x0005b;31&#x0005d;</xref>. <xref ref-type="fig" rid="pone-0005843-g003">Fig. 3.b and c</xref> show two locations from the same histological slide representing two regions with different degree of angiogenesis as indicated by the different levels of VEGFR-2. Of note, more nanoprobes deposited in the region of high levels (<xref ref-type="fig" rid="pone-0005843-g003">Fig. 3.b</xref>) than low levels of VEGFR-2 (<xref ref-type="fig" rid="pone-0005843-g003">Fig. 3.c</xref>). The deposition of the nanoprobes usually coincided with the regions of high levels of VEGFR-2 which indicates leakier blood vessels. Thus, these data corroborate the imaging data and are consistent with enhanced accumulation of nanoprobes in regions of high angiogenic activity.</p><fig id="pone-0005843-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005843.g003</object-id><label>Figure 3</label><caption><title>Histological evaluation of the intratumoral microdistribution of the probe and VEGFR-2.</title><p>(a) The nanoprobes (shown in red) localized in the periphery of the tumor showing a patchy distribution (DAPI was used as a nuclear stain; shown in blue; 4&#x000d7; magnification). In the same slide, the highly vascularized peripheral rim is shown to have high levels of VEGFR-2 (shown in green) compared to the less vascularized inner core. (b) High intratumoral deposition of the nanoprobe is found in a region with high levels of VEGFR-2. (c) Relatively few nanoprobes accumulated in a region of low VEGFR-2 levels.</p></caption><graphic xlink:href="pone.0005843.g003"/></fig></sec><sec id="s3d"><title>Correlation of tumor growth to imaging of EPR</title><p>To evaluate whether the degree of EPR scales to the tumor growth rate, a different group of animals (group B) was imaged before and after IV injection of the probe and the tumor growth of each animal was measured for several days after imaging. Similarly to before, the tumor enhancement profiles exhibited dissimilar patterns in different animals (<xref ref-type="fig" rid="pone-0005843-g004">Fig. 4.a</xref>). <xref ref-type="fig" rid="pone-0005843-g004">Fig. 4.b</xref> shows the tumor growth rate of each individual animal displaying a wide variability. Importantly, a significant correlation between the imaging measurements and the tumor growth was observed. Higher intratumoral deposition of the nanocarrier as imaged with mammography indicating leakier vasculature correlated to a faster tumor growth rate. To quantitatively understand the relation of the imaging measurement and tumor growth, we calculated the tumor growth rate constant (K<sup>tumor growth</sup>) and signal enhancement rate constant (K<sup>enhancement</sup>) of each animal. <xref ref-type="fig" rid="pone-0005843-g004">Fig. 4.c</xref> demonstrates a strong correlation between K<sup>tumor growth</sup> and K<sup>enhancement</sup> with the more leaky tumors (high K<sup>enhancement</sup>) having faster tumor progress (high K<sup>tumor growth</sup>) and vice versa.</p><fig id="pone-0005843-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005843.g004</object-id><label>Figure 4</label><caption><title>Comparison of the imaging-based measurement of tumor EPR to tumor growth rate.</title><p>(a) The 4-day pattern of the enhancement following injection of the probe (455 mg/kg iodine) to a group of rats (n&#x0200a;&#x0003d;&#x0200a;11) indicated a high variability in the tumors leakiness. (b) The tumor of each animal displayed a different growth rate as indicated by the variable tumor growth curves. (c) The correlation of the tumor growth (K<sup>tumor growth</sup>) and the imaging measurement (K<sup>enhancement</sup>) was statistically significant (R<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;0.785; p&#x0003c;0.001).</p></caption><graphic xlink:href="pone.0005843.g004"/></fig></sec></sec><sec id="s4"><title>Discussion</title><p>Clinical studies have shown the VEGF expression varies among tumors <xref ref-type="bibr" rid="pone.0005843-Gasparini1">&#x0005b;14&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005843-Linderholm1">&#x0005b;16&#x0005d;</xref>. In this study, we also observed a high variability in the expression of tumor VEGF-A and VEGFR-2 among the different animals (as measured by qRT-PCR) with the standard deviation being 37 and 52&#x00025; of the mean value, respectively. This is consistent with a previous study that reported similar variability of angiogenesis biomarkers in animal tumor models <xref ref-type="bibr" rid="pone.0005843-Heffelfinger1">&#x0005b;37&#x0005d;</xref>. The imaging data verified our hypothesis that the higher expression of angiogenic biomarkers in specific tumors resulted in more permeable blood vessels which subsequently resulted in greater intratumoral accumulation of the nanoprobe. Not surprisingly, we observed that the tumor EPR (as measured by mammography) varied widely from one animal to the next which is consistent with previous studies demonstrating a wide variation in the intratumoral accumulation of nanoscale liposomal agents within tumors of the same &#x02018;stage&#x02019; and size in preclinical <xref ref-type="bibr" rid="pone.0005843-McNeeley1">&#x0005b;38&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005843-Drummond1">&#x0005b;42&#x0005d;</xref> and clinical studies <xref ref-type="bibr" rid="pone.0005843-Harrington1">&#x0005b;43&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005843-Northfelt1">&#x0005b;44&#x0005d;</xref>. Actually, it is well established that the degree of tumor vasculature leakiness differs not only among same type tumors but even spatially within the same tumor <xref ref-type="bibr" rid="pone.0005843-Fukumura1">&#x0005b;45&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005843-Yuan1">&#x0005b;47&#x0005d;</xref>.</p><p>Furthermore, the tumors with the leakier blood vessels were the ones with the faster growth rates. Even though the tumor model was developed in a controlled manner by inoculating the same type and number of cells into the same location of rats with the same age and weight, a wide range of tumor growth rates was observed (the standard deviation was about 30&#x00025; of the mean value). The variable tumor growth rate observed in our study is consistent with human breast tumor xenografts in nude mice where the tumor growth curve had standard deviations of about 15&#x02013;25&#x00025; of the mean value <xref ref-type="bibr" rid="pone.0005843-Park1">&#x0005b;39&#x0005d;</xref>. Our results display one more example that tumors represent a very heterogeneous population of different cells with a complex microenvironment that is strongly affected by angiogenesis. Notably, many clinical studies have shown that increased VEGF overexpression in breast tumors correlate with more unfavorable prognosis <xref ref-type="bibr" rid="pone.0005843-Gasparini1">&#x0005b;14&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005843-Kim1">&#x0005b;17&#x0005d;</xref>. In another clinical study <xref ref-type="bibr" rid="pone.0005843-Vamesu1">&#x0005b;48&#x0005d;</xref>, analysis of core biopsies from 155 breast cancer patients showed that tumor angiogenesis correlated with tumor histological analysis suggesting that assessment of tumor angiogenesis can be used as a selection criterion for patients to undergo a more aggressive therapeutic protocol.</p><p>The feasibility of our imaging method to evaluate tumor angiogenesis was demonstrated on a single tumor model although human cancer as a disease is much more heterogeneous than one experimental tumor model in terms of both tumors and hosts <xref ref-type="bibr" rid="pone.0005843-Wagner1">&#x0005b;49&#x0005d;</xref>. The MAT BIII tumor and its vasculature grow rapidly while human tumors exhibit a range of growth rates. To address this variability in tumor growth rates and its relationship to their EPR and angiogenesis status, further testing in more tumor models is required to capture the proliferative range of human tumors.</p><p>The significance of tumor vascular permeability and its association to angiogenesis, tumor growth, metastatic tendency, and delivery of macromolecular and nanoscale therapeutics has been well documented and debated <xref ref-type="bibr" rid="pone.0005843-McDonald1">&#x0005b;50&#x0005d;</xref>. We have recently shown that tumor vascular permeability governs the access of therapeutic agents to tumors <xref ref-type="bibr" rid="pone.0005843-Karathanasis1">&#x0005b;30&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005843-Karathanasis2">&#x0005b;31&#x0005d;</xref>. The current study indicates that vessel leakiness is strongly associated with the environment of tumors, the tumor growth and the rate of angiogenesis. Such non-invasive, imaging method can potentially provide an <italic>a priori</italic> determination of the degree of tumor aggressiveness and facilitate personalized therapy. In addition, the realization of the effects of tumor angiogenesis on tumor growth and metastasis <xref ref-type="bibr" rid="pone.0005843-Folkman1">&#x0005b;3&#x0005d;</xref> has led to the development of anti-angiogenic therapeutic strategies for the treatment of malignant tumors by targeting VEGF signaling <xref ref-type="bibr" rid="pone.0005843-Ferrara2">&#x0005b;2&#x0005d;</xref>. Besides tumor staging and size, the clinician typically has little information to design, track and customize the anti-angiogenic therapy for each tumor in a patient-specific manner <xref ref-type="bibr" rid="pone.0005843-Miller1">&#x0005b;20&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005843-Drevs1">&#x0005b;51&#x0005d;</xref>. To date, there exist no clinical tools to determine the tumor VEGF expression profile enabling identification of the patients who can possibly benefit from such therapies. In addition, the ability to assess VEGF target inhibition independently of tumor response is critical for these agents, since long times are usually required for changes in tumor growth to become apparent. One recent example demonstrating the critical role that tumor vasculature plays in determining outcomes of antiangiogenic therapies comes from the work of Jain <xref ref-type="bibr" rid="pone.0005843-Jain1">&#x0005b;52&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005843-Fukumura2">&#x0005b;53&#x0005d;</xref>, where it is demonstrated that the restructuring of tumor vasculature (a process termed &#x02018;normalization&#x02019;) leads to better chemotherapeutic outcomes. While antiangiogenic agents focus on destroying tumor related blood vessels compromising the efficiency of subsequent chemotherapy, optimal scheduling and dosing of these therapies can &#x02018;normalize&#x02019; the abnormal tumor vasculature for better delivery of oxygen (eliminating hypoxia and its complications) and drugs. Measurement of vessel leakiness using our nanoprobe and mammography can potentially provide prognostic assessment and monitoring of anti-angiogenic therapies of breast cancer. We hypothesize such strategy would also be possible with tomographic methods (e.g. CT) extending the application to other types of cancer.</p></sec></body><back><ack><p>The authors wish to thank Dr. Ketan B. Ghaghada for useful discussions, Sonia Im for her help with histology and Vijal Patel for his help with analysis of radiographic images.</p></ack><ref-list><title>References</title><ref id="pone.0005843-Ferrara1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferrara</surname><given-names>N</given-names></name><name><surname>Gerber</surname><given-names>HP</given-names></name><name><surname>LeCouter</surname><given-names>J</given-names></name></person-group><year>2003</year><article-title>The biology of VEGF and its receptors.</article-title><source>Nat Med</source><volume>9</volume><fpage>669</fpage><lpage>676</lpage><pub-id pub-id-type="pmid">12778165</pub-id></citation></ref><ref id="pone.0005843-Ferrara2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferrara</surname><given-names>N</given-names></name><name><surname>Kerbel</surname><given-names>RS</given-names></name></person-group><year>2005</year><article-title>Angiogenesis as a therapeutic target.</article-title><source>Nature</source><volume>438</volume><fpage>967</fpage><lpage>974</lpage><pub-id pub-id-type="pmid">16355214</pub-id></citation></ref><ref id="pone.0005843-Folkman1"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Folkman</surname><given-names>J</given-names></name></person-group><year>1995</year><article-title>Angiogenesis in cancer, vascular, rheumatoid and other disease.</article-title><source>Nat Med</source><volume>1</volume><fpage>27</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">7584949</pub-id></citation></ref><ref id="pone.0005843-Folkman2"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Folkman</surname><given-names>J</given-names></name></person-group><year>1990</year><article-title>What is the evidence that tumors are angiogenesis dependent?</article-title><source>J Natl Cancer Inst</source><volume>82</volume><fpage>4</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">1688381</pub-id></citation></ref><ref id="pone.0005843-StetlerStevenson1"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stetler-Stevenson</surname><given-names>WG</given-names></name></person-group><year>2001</year><article-title>The role of matrix metalloproteinases in tumor invasion, metastasis, and angiogenesis.</article-title><source>Surg Oncol Clin N Am</source><volume>10</volume><fpage>383</fpage><lpage>392</lpage><comment>x</comment><pub-id pub-id-type="pmid">11382593</pub-id></citation></ref><ref id="pone.0005843-Ferrara3"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferrara</surname><given-names>N</given-names></name></person-group><year>2005</year><article-title>The role of VEGF in the regulation of physiological and pathological angiogenesis.</article-title><source>EXS</source><fpage>209</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">15617481</pub-id></citation></ref><ref id="pone.0005843-YamajiKegan1"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamaji-Kegan</surname><given-names>K</given-names></name><name><surname>Su</surname><given-names>Q</given-names></name><name><surname>Angelini</surname><given-names>DJ</given-names></name><name><surname>Champion</surname><given-names>HC</given-names></name><name><surname>Johns</surname><given-names>RA</given-names></name></person-group><year>2006</year><article-title>Hypoxia-induced mitogenic factor has proangiogenic and proinflammatory effects in the lung via VEGF and VEGF receptor-2.</article-title><source>Am J Physiol Lung Cell Mol Physiol</source><volume>291</volume><fpage>L1159</fpage><lpage>1168</lpage><pub-id pub-id-type="pmid">16891392</pub-id></citation></ref><ref id="pone.0005843-Shibuya1"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shibuya</surname><given-names>M</given-names></name></person-group><year>2006</year><article-title>Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis.</article-title><source>J Biochem Mol Biol</source><volume>39</volume><fpage>469</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">17002866</pub-id></citation></ref><ref id="pone.0005843-CebeSuarez1"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cebe-Suarez</surname><given-names>S</given-names></name><name><surname>Zehnder-Fjallman</surname><given-names>A</given-names></name><name><surname>Ballmer-Hofer</surname><given-names>K</given-names></name></person-group><year>2006</year><article-title>The role of VEGF receptors in angiogenesis; complex partnerships.</article-title><source>Cell Mol Life Sci</source><volume>63</volume><fpage>601</fpage><lpage>615</lpage><pub-id pub-id-type="pmid">16465447</pub-id></citation></ref><ref id="pone.0005843-Fox1"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>SB</given-names></name><name><surname>Generali</surname><given-names>DG</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name></person-group><year>2007</year><article-title>Breast tumour angiogenesis.</article-title><source>Breast Cancer Res</source><volume>9</volume><fpage>216</fpage><pub-id pub-id-type="pmid">18190723</pub-id></citation></ref><ref id="pone.0005843-Relf1"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Relf</surname><given-names>M</given-names></name><name><surname>LeJeune</surname><given-names>S</given-names></name><name><surname>Scott</surname><given-names>PA</given-names></name><name><surname>Fox</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>K</given-names></name><etal/></person-group><year>1997</year><article-title>Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis.</article-title><source>Cancer Res</source><volume>57</volume><fpage>963</fpage><lpage>969</lpage><pub-id pub-id-type="pmid">9041202</pub-id></citation></ref><ref id="pone.0005843-Fox2"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>SB</given-names></name><name><surname>Gasparini</surname><given-names>G</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name></person-group><year>2001</year><article-title>Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs.</article-title><source>Lancet Oncol</source><volume>2</volume><fpage>278</fpage><lpage>289</lpage><pub-id pub-id-type="pmid">11905783</pub-id></citation></ref><ref id="pone.0005843-Nikitenko1"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nikitenko</surname><given-names>LL</given-names></name><name><surname>Fox</surname><given-names>SB</given-names></name><name><surname>Kehoe</surname><given-names>S</given-names></name><name><surname>Rees</surname><given-names>MC</given-names></name><name><surname>Bicknell</surname><given-names>R</given-names></name></person-group><year>2006</year><article-title>Adrenomedullin and tumour angiogenesis.</article-title><source>Br J Cancer</source><volume>94</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">16251875</pub-id></citation></ref><ref id="pone.0005843-Gasparini1"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gasparini</surname><given-names>G</given-names></name></person-group><year>2000</year><article-title>Prognostic value of vascular endothelial growth factor in breast cancer.</article-title><source>Oncologist</source><volume>5</volume><issue>Suppl 1</issue><fpage>37</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">10804090</pub-id></citation></ref><ref id="pone.0005843-Gasparini2"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gasparini</surname><given-names>G</given-names></name></person-group><year>2001</year><article-title>Clinical significance of determination of surrogate markers of angiogenesis in breast cancer.</article-title><source>Crit Rev Oncol Hematol</source><volume>37</volume><fpage>97</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">11166583</pub-id></citation></ref><ref id="pone.0005843-Linderholm1"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Linderholm</surname><given-names>B</given-names></name><name><surname>Tavelin</surname><given-names>B</given-names></name><name><surname>Grankvist</surname><given-names>K</given-names></name><name><surname>Henriksson</surname><given-names>R</given-names></name></person-group><year>1998</year><article-title>Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma.</article-title><source>J Clin Oncol</source><volume>16</volume><fpage>3121</fpage><lpage>3128</lpage><pub-id pub-id-type="pmid">9738584</pub-id></citation></ref><ref id="pone.0005843-Kim1"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>EA</given-names></name><name><surname>Gershtein</surname><given-names>ES</given-names></name><name><surname>Vysotskaya</surname><given-names>IV</given-names></name><name><surname>Kushlinskii</surname><given-names>NE</given-names></name></person-group><year>2008</year><article-title>Expression of VEGF and VEGFR2 in tumors during neoadjuvant therapy of patients with breast cancer.</article-title><source>Bull Exp Biol Med</source><volume>145</volume><fpage>245</fpage><lpage>248</lpage><pub-id pub-id-type="pmid">19023980</pub-id></citation></ref><ref id="pone.0005843-Raatschen1"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Raatschen</surname><given-names>HJ</given-names></name><name><surname>Simon</surname><given-names>GH</given-names></name><name><surname>Fu</surname><given-names>Y</given-names></name><name><surname>Sennino</surname><given-names>B</given-names></name><name><surname>Shames</surname><given-names>DM</given-names></name><etal/></person-group><year>2008</year><article-title>Vascular permeability during antiangiogenesis treatment: MR imaging assay results as biomarker for subsequent tumor growth in rats.</article-title><source>Radiology</source><volume>247</volume><fpage>391</fpage><lpage>399</lpage><pub-id pub-id-type="pmid">18372448</pub-id></citation></ref><ref id="pone.0005843-Hylton1"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hylton</surname><given-names>N</given-names></name></person-group><year>2006</year><article-title>Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker.</article-title><source>J Clin Oncol</source><volume>24</volume><fpage>3293</fpage><lpage>3298</lpage><pub-id pub-id-type="pmid">16829653</pub-id></citation></ref><ref id="pone.0005843-Miller1"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>JC</given-names></name><name><surname>Pien</surname><given-names>HH</given-names></name><name><surname>Sahani</surname><given-names>D</given-names></name><name><surname>Sorensen</surname><given-names>AG</given-names></name><name><surname>Thrall</surname><given-names>JH</given-names></name></person-group><year>2005</year><article-title>Imaging angiogenesis: applications and potential for drug development.</article-title><source>J Natl Cancer Inst</source><volume>97</volume><fpage>172</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">15687360</pub-id></citation></ref><ref id="pone.0005843-Nunes1"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nunes</surname><given-names>FL</given-names></name><name><surname>Schiabel</surname><given-names>H</given-names></name><name><surname>Benatti</surname><given-names>RH</given-names></name></person-group><year>2002</year><article-title>Contrast enhancement in dense breast images using the modulation transfer function.</article-title><source>Med Phys</source><volume>29</volume><fpage>2925</fpage><lpage>2936</lpage><pub-id pub-id-type="pmid">12512729</pub-id></citation></ref><ref id="pone.0005843-Brix1"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brix</surname><given-names>G</given-names></name><name><surname>Semmler</surname><given-names>W</given-names></name><name><surname>Port</surname><given-names>R</given-names></name><name><surname>Schad</surname><given-names>LR</given-names></name><name><surname>Layer</surname><given-names>G</given-names></name><etal/></person-group><year>1991</year><article-title>Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging.</article-title><source>J Comput Assist Tomogr</source><volume>15</volume><fpage>621</fpage><lpage>628</lpage><pub-id pub-id-type="pmid">2061479</pub-id></citation></ref><ref id="pone.0005843-Larsson1"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Larsson</surname><given-names>HBW</given-names></name><name><surname>Stubgaard</surname><given-names>M</given-names></name><name><surname>Frederiksen</surname><given-names>JL</given-names></name><name><surname>Jensen</surname><given-names>M</given-names></name><name><surname>Henriksen</surname><given-names>O</given-names></name><etal/></person-group><year>1990</year><article-title>Quantitation of blood-brain barrier defects by magnetic resonance imaging and gadolinium-DTPA in patients with multiple sclerosis and brain tumors.</article-title><source>Magn Reson Med</source><volume>16</volume><fpage>117</fpage><lpage>131</lpage><pub-id pub-id-type="pmid">2255233</pub-id></citation></ref><ref id="pone.0005843-Tofts1"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tofts</surname><given-names>PS</given-names></name><name><surname>Kermode</surname><given-names>AG</given-names></name></person-group><year>1991</year><article-title>Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging.</article-title><source>Magn Reson Med</source><volume>17</volume><fpage>357</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">2062210</pub-id></citation></ref><ref id="pone.0005843-Tofts2"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tofts</surname><given-names>PS</given-names></name></person-group><year>1997</year><article-title>Modeling tracer kinetics in dynamic Gd-DTPA MR imaging.</article-title><source>J Magn Reson Imaging</source><volume>7</volume><fpage>91</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">9039598</pub-id></citation></ref><ref id="pone.0005843-Chen1"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Cai</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>ZB</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name></person-group><year>2009</year><article-title>Quantitative PET Imaging of VEGF Receptor Expression.</article-title><source>Mol Imaging Biol</source><volume>11</volume><fpage>15</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">18784964</pub-id></citation></ref><ref id="pone.0005843-Chen2"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>ZB</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Cai</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name></person-group><year>2008</year><article-title>Dual-modality optical and positron emission tomography imaging of vascular endothelial growth factor receptor on tumor vasculature using quantum dots.</article-title><source>Eur J Nucl Med Mol Imaging</source><volume>35</volume><fpage>2235</fpage><lpage>2244</lpage><pub-id pub-id-type="pmid">18566815</pub-id></citation></ref><ref id="pone.0005843-Maeda1"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maeda</surname><given-names>H</given-names></name></person-group><year>2001</year><article-title>SMANCS and Polymer-Conjugated Macromolecular Drugs: Advantages in Cancer Chemotherapy.</article-title><source>Adv Drug Deliv Rev</source><volume>46</volume><fpage>169</fpage><lpage>185</lpage><pub-id pub-id-type="pmid">11259839</pub-id></citation></ref><ref id="pone.0005843-Maeda2"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maeda</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Sawa</surname><given-names>T</given-names></name><name><surname>Matsumura</surname><given-names>Y</given-names></name><name><surname>Hori</surname><given-names>K</given-names></name></person-group><year>2000</year><article-title>Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review.</article-title><source>J Control Release</source><volume>65</volume><fpage>271</fpage><lpage>284</lpage><pub-id pub-id-type="pmid">10699287</pub-id></citation></ref><ref id="pone.0005843-Karathanasis1"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karathanasis</surname><given-names>E</given-names></name><name><surname>Chan</surname><given-names>L</given-names></name><name><surname>Balusu</surname><given-names>SR</given-names></name><name><surname>D'Orsi</surname><given-names>CJ</given-names></name><name><surname>Annapragada</surname><given-names>AV</given-names></name><etal/></person-group><year>2008</year><article-title>Multifunctional nanocarriers for mammographic quantification of tumor dosing and prognosis of breast cancer therapy.</article-title><source>Biomaterials</source><volume>29</volume><fpage>4815</fpage><lpage>4822</lpage><pub-id pub-id-type="pmid">18814908</pub-id></citation></ref><ref id="pone.0005843-Karathanasis2"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karathanasis</surname><given-names>E</given-names></name><name><surname>Suryanarayanan</surname><given-names>S</given-names></name><name><surname>Balusu</surname><given-names>SR</given-names></name><name><surname>McNeeley</surname><given-names>K</given-names></name><name><surname>Sechopoulos</surname><given-names>I</given-names></name><etal/></person-group><year>2009</year><article-title>Imaging nanoprobe for prediction of outcome of nanoparticle chemotherapy by using mammography.</article-title><source>Radiology</source><volume>250</volume><fpage>398</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">19188313</pub-id></citation></ref><ref id="pone.0005843-Pisano1"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pisano</surname><given-names>ED</given-names></name><name><surname>Gatsonis</surname><given-names>C</given-names></name><name><surname>Hendrick</surname><given-names>E</given-names></name><name><surname>Yaffe</surname><given-names>M</given-names></name><name><surname>Baum</surname><given-names>JK</given-names></name><etal/></person-group><year>2005</year><article-title>Diagnostic performance of digital versus film mammography for breast-cancer screening.</article-title><source>N Engl J Med</source><volume>353</volume><fpage>1773</fpage><lpage>1783</lpage><pub-id pub-id-type="pmid">16169887</pub-id></citation></ref><ref id="pone.0005843-Hubbell1"><label>33</label><citation citation-type="other"><person-group person-group-type="author"><name><surname>Hubbell</surname><given-names>JH</given-names></name><name><surname>Seltzer</surname><given-names>SM</given-names></name></person-group><year>1996</year><article-title>Tables of X-Ray Mass Attenuation Coefficients and Mass Energy-Absorption Coefficients.</article-title><comment>Accessed 12/05/2007; <ext-link ext-link-type="uri" xlink:href="http://physics.nist.gov/PhysRefData/XrayMassCoef/cover.html">http://physics.nist.gov/PhysRefData/XrayMassCoef/cover.html</ext-link></comment></citation></ref><ref id="pone.0005843-Karathanasis3"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karathanasis</surname><given-names>E</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Agarwal</surname><given-names>A</given-names></name><name><surname>Patel</surname><given-names>V</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><etal/></person-group><year>2008</year><article-title>MRI mediated, non-invasive tracking of intratumoral distribution of nanocarriers in rat glioma.</article-title><source>Nanotechnology</source><volume>19</volume><fpage>315101(315109pp)</fpage></citation></ref><ref id="pone.0005843-Brown1"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>BW</given-names></name><name><surname>Atkinson</surname><given-names>EN</given-names></name><name><surname>Bartoszynski</surname><given-names>R</given-names></name><name><surname>Thompson</surname><given-names>JR</given-names></name><name><surname>Montague</surname><given-names>ED</given-names></name></person-group><year>1984</year><article-title>Estimation of human tumor growth rate from distribution of tumor size at detection.</article-title><source>J Natl Cancer Inst</source><volume>72</volume><fpage>31</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">6582302</pub-id></citation></ref><ref id="pone.0005843-Lasic1"><label>36</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Lasic</surname><given-names>D</given-names></name><name><surname>Martin</surname><given-names>F</given-names></name></person-group><year>1995</year><source>Stealth Liposomes</source><publisher-name>CRC Press Inc</publisher-name></citation></ref><ref id="pone.0005843-Heffelfinger1"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heffelfinger</surname><given-names>SC</given-names></name><name><surname>Yan</surname><given-names>M</given-names></name><name><surname>Gear</surname><given-names>RB</given-names></name><name><surname>Schneider</surname><given-names>J</given-names></name><name><surname>LaDow</surname><given-names>K</given-names></name><etal/></person-group><year>2004</year><article-title>Inhibition of VEGFR2 prevents DMBA-induced mammary tumor formation.</article-title><source>Lab Invest</source><volume>84</volume><fpage>989</fpage><lpage>998</lpage><pub-id pub-id-type="pmid">15170218</pub-id></citation></ref><ref id="pone.0005843-McNeeley1"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McNeeley</surname><given-names>KM</given-names></name><name><surname>Annapragada</surname><given-names>A</given-names></name><name><surname>Bellamkonda</surname><given-names>RV</given-names></name></person-group><year>2007</year><article-title>Decreased circulation time offsets increased efficacy of PEGylated nanocarriers targeting folate receptors of glioma.</article-title><source>Nanotechnology</source><volume>18</volume><fpage>385101</fpage></citation></ref><ref id="pone.0005843-Park1"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JW</given-names></name><name><surname>Hong</surname><given-names>K</given-names></name><name><surname>Kirpotin</surname><given-names>DB</given-names></name><name><surname>Colbern</surname><given-names>G</given-names></name><name><surname>Shalaby</surname><given-names>R</given-names></name><etal/></person-group><year>2002</year><article-title>Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.</article-title><source>Clin Cancer Res</source><volume>8</volume><fpage>1172</fpage><lpage>1181</lpage><pub-id pub-id-type="pmid">11948130</pub-id></citation></ref><ref id="pone.0005843-Kirpotin1"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kirpotin</surname><given-names>DB</given-names></name><name><surname>Drummond</surname><given-names>DC</given-names></name><name><surname>Shao</surname><given-names>Y</given-names></name><name><surname>Shalaby</surname><given-names>MR</given-names></name><name><surname>Hong</surname><given-names>K</given-names></name><etal/></person-group><year>2006</year><article-title>Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.</article-title><source>Cancer Res</source><volume>66</volume><fpage>6732</fpage><lpage>6740</lpage><pub-id pub-id-type="pmid">16818648</pub-id></citation></ref><ref id="pone.0005843-Saucier1"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saucier</surname><given-names>JM</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Gaikwad</surname><given-names>A</given-names></name><name><surname>Coleman</surname><given-names>RL</given-names></name><name><surname>Wolf</surname><given-names>JK</given-names></name><etal/></person-group><year>2007</year><article-title>Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model.</article-title><source>J Oncol Pharm Pract</source><volume>13</volume><fpage>39</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">17621566</pub-id></citation></ref><ref id="pone.0005843-Drummond1"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Drummond</surname><given-names>DC</given-names></name><name><surname>Meyer</surname><given-names>O</given-names></name><name><surname>Hong</surname><given-names>K</given-names></name><name><surname>Kirpotin</surname><given-names>DB</given-names></name><name><surname>Papahadjopoulos</surname><given-names>D</given-names></name></person-group><year>1999</year><article-title>Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors.</article-title><source>Pharmacol Rev</source><volume>51</volume><fpage>691</fpage><lpage>743</lpage><pub-id pub-id-type="pmid">10581328</pub-id></citation></ref><ref id="pone.0005843-Harrington1"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harrington</surname><given-names>KJ</given-names></name><name><surname>Mohammadtaghi</surname><given-names>S</given-names></name><name><surname>Uster</surname><given-names>PS</given-names></name><name><surname>Glass</surname><given-names>D</given-names></name><name><surname>Peters</surname><given-names>AM</given-names></name><etal/></person-group><year>2001</year><article-title>Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes.</article-title><source>Clin Cancer Res</source><volume>7</volume><fpage>243</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">11234875</pub-id></citation></ref><ref id="pone.0005843-Northfelt1"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Northfelt</surname><given-names>DW</given-names></name><name><surname>Martin</surname><given-names>FJ</given-names></name><name><surname>Working</surname><given-names>P</given-names></name><name><surname>Volberding</surname><given-names>PA</given-names></name><name><surname>Russell</surname><given-names>J</given-names></name><etal/></person-group><year>1996</year><article-title>Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma.</article-title><source>J Clin Pharmacol</source><volume>36</volume><fpage>55</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">8932544</pub-id></citation></ref><ref id="pone.0005843-Fukumura1"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fukumura</surname><given-names>D</given-names></name><name><surname>Jain</surname><given-names>RK</given-names></name></person-group><year>2007</year><article-title>Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize.</article-title><source>J Cell Biochem</source><volume>101</volume><fpage>937</fpage><lpage>949</lpage><pub-id pub-id-type="pmid">17171643</pub-id></citation></ref><ref id="pone.0005843-Hobbs1"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hobbs</surname><given-names>SK</given-names></name><name><surname>Monsky</surname><given-names>WL</given-names></name><name><surname>Yuan</surname><given-names>F</given-names></name><name><surname>Roberts</surname><given-names>WG</given-names></name><name><surname>Griffith</surname><given-names>L</given-names></name><etal/></person-group><year>1998</year><article-title>Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment.</article-title><source>Proc Natl Acad Sci U S A</source><volume>95</volume><fpage>4607</fpage><lpage>4612</lpage><pub-id pub-id-type="pmid">9539785</pub-id></citation></ref><ref id="pone.0005843-Yuan1"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Dellian</surname><given-names>M</given-names></name><name><surname>Safabakhsh</surname><given-names>N</given-names></name><name><surname>Ferrara</surname><given-names>N</given-names></name><etal/></person-group><year>1996</year><article-title>Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody.</article-title><source>Proc Natl Acad Sci U S A</source><volume>93</volume><fpage>14765</fpage><lpage>14770</lpage><pub-id pub-id-type="pmid">8962129</pub-id></citation></ref><ref id="pone.0005843-Vamesu1"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vamesu</surname><given-names>S</given-names></name></person-group><year>2008</year><article-title>Angiogenesis and tumor histologic type in primary breast cancer patients: an analysis of 155 needle core biopsies.</article-title><source>Rom J Morphol Embryol</source><volume>49</volume><fpage>181</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">18516324</pub-id></citation></ref><ref id="pone.0005843-Wagner1"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>KU</given-names></name></person-group><year>2004</year><article-title>Models of breast cancer: quo vadis, animal modeling?</article-title><source>Breast Cancer Res</source><volume>6</volume><fpage>31</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">14680483</pub-id></citation></ref><ref id="pone.0005843-McDonald1"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McDonald</surname><given-names>DM</given-names></name><name><surname>Baluk</surname><given-names>P</given-names></name></person-group><year>2002</year><article-title>Significance of blood vessel leakiness in cancer.</article-title><source>Cancer Res</source><volume>62</volume><fpage>5381</fpage><lpage>5385</lpage><pub-id pub-id-type="pmid">12235011</pub-id></citation></ref><ref id="pone.0005843-Drevs1"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Drevs</surname><given-names>J</given-names></name><name><surname>Schneider</surname><given-names>V</given-names></name></person-group><year>2006</year><article-title>The use of vascular biomarkers and imaging studies in the early clinical development of anti-tumour agents targeting angiogenesis.</article-title><source>J Intern Med</source><volume>260</volume><fpage>517</fpage><lpage>529</lpage><pub-id pub-id-type="pmid">17116002</pub-id></citation></ref><ref id="pone.0005843-Jain1"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>RK</given-names></name></person-group><year>2005</year><article-title>Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy.</article-title><source>Science</source><volume>307</volume><fpage>58</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">15637262</pub-id></citation></ref><ref id="pone.0005843-Fukumura2"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fukumura</surname><given-names>D</given-names></name><name><surname>Jain</surname><given-names>RK</given-names></name></person-group><year>2007</year><article-title>Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization.</article-title><source>Microvasc Res</source></citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>Some of the nano-scale contrast agents for CT developed by the authors has been licensed by a start-up company, Marval Biosciences Inc, in which the authors have a financial interest.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This project was supported in part by National Science Foundation Bioengineering and Environmental Systems 0401627 (RVB), Georgia Tech/Emory Center for Engineering Living Tissues an NSF ERC - EEC-9731643 (RVB), the Nora Reed Foundation (RVB), the Wallace H. Coulter Foundation (RVB), and the Georgia Cancer Coalition (RVB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article> 